Annika de Jong

Annika de Jong

Auto-generated profile, based on publicly available information

Annika de Jong

Department of Internal medicine, division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2015 in Epigenetics
Verified
Journal Article
Open access
JBJudit Balog
Judit Balog
PTPeter E. Thijssen
Peter E. Thijssen
SSSean Shadle
Sean Shadle
KSKirsten R. Straasheijm
Kirsten R. Straasheijm
PVPatrick J. van der Vliet
Patrick J. van der Vliet
SMSilvere M. Van der Maarel
Silvere M. Van der Maarel
Facioscapulohumeral muscular dystrophy is caused by incomplete epigenetic repression of the transcription factor DUX4 in skeletal muscle. A copy of DUX4 is located within each unit of the D4Z4 macrosatellite repeat array and its derepression in somatic cells is caused by either repeat array contraction (FSHD1) or by mutations in the chromatin repressor SMCHD1 (FSHD2). While DUX4 expression has thus far only been detected in FSHD muscle and muscle cell cultures, and increases with in vitro myogenic differentiation, the D4Z4 chromatin structure has only been studied in proliferating myoblasts or non-myogenic cells. We here show that SMCHD1 protein levels at D4Z4 decline during muscle cell differentiation and correlate with DUX4 derepression. In FSHD2, but not FSHD1, the loss of SMCHD1 repressor activity is partially compensated by increased Polycomb Repressive Complex 2 (PRC2)–mediated H3K27 trimethylation at D4Z4, a situation that can be mimicked by SMCHD1 knockdown in control myotubes. In contrast, moderate overexpression of SMCHD1 results in DUX4 silencing in FSHD1 and FSHD2 myotubes demonstrating that DUX4 derepression in FSHD is reversible. Together, we show that in FSHD1 and FSHD2 the decline in SMCHD1 protein levels during muscle cell differentiation renders skeletal muscle sensitive to DUX4.

1 November 2017 in Thrombosis Research
Verified
Journal Article
Closed access
AJAnnika de Jong
Annika de Jong
JEJeroen Eikenboom
Jeroen Eikenboom

1 March 2016 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
AJA. De Jong
A. De Jong
JEJeroen Eikenboom
Jeroen Eikenboom

1 October 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
SBSuzan de Boer
Suzan de Boer
MBMackenzie Bowman
Mackenzie Bowman
CNColleen Notley
Colleen Notley
AMAomei Mo
Aomei Mo
PLPatricia Lima
Patricia Lima
JEJeroen Eikenboom
Jeroen Eikenboom
Endothelial colony forming cells (ECFCs) derived from peripheral blood can be used to analyze the pathophysiology of vascular diseases ex vivo. However, heterogeneity is observed between ECFC clones and this variability needs to be understood and standardized for ECFCs to be used as a cell model for applications in vascular studies. Determine reference characteristics of healthy control ECFCs to generate a valid ex vivo model for vascular disease. Putative ECFCs (n = 47) derived from 21 individual healthy subjects were studied for cell morphology and specific cell characteristics. Clones were analyzed for the production and secretion of von Willebrand factor (VWF), cell proliferation, and the expression of endothelial cell markers. Based on morphology, clones were categorized into three groups. Group 1 consisted of clones with classic endothelial cell morphology, whereas groups 2 and 3 contained less condensed cells with increasing cell sizes. All clones had comparable endothelial cell surface expression profiles, with low levels of non‐endothelial markers. However, a decrease in CD31 and a group‐related increase in CD309 and CD45 expression, combined with a decrease in cell proliferation and VWF production and secretion, was observed in clones in group 3 and to a lesser extent in group 2. We observed group‐related variations in endothelial cell characteristics when clones lacked the classic endothelial cell morphology. Despite this variation, clones in all groups expressed endothelial cell surface markers. Provided that clones with similar characteristics are compared, we believe ECFCs are a valid ex vivo model to study vascular disease.

7 May 2018 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
AJA. de Jong
A. de Jong
RDRichard Dirven
Richard Dirven
JOJ. A. Oud
J. A. Oud
DTD. Tio
D. Tio
BVB. J. M van Vlijmen
B. J. M van Vlijmen
JEJeroen Eikenboom
Jeroen Eikenboom

15 August 2020 in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
AJAnnika de Jong
Annika de Jong
RDRichard Dirven
Richard Dirven
JBJohan Boender
Johan Boender
FAFerdows Atiq
Ferdows Atiq
SASeyed Yahya Anvar
Seyed Yahya Anvar
JEJeroen Eikenboom
Jeroen Eikenboom
Von Willebrand disease (VWD) is the most common inherited bleeding disorder and is mainly caused by dominant-negative mutations in the multimeric protein von Willebrand factor (VWF). These mutations may either result in quantitative or qualitative defects in VWF. VWF is an endothelial protein that is secreted to the circulation upon endothelial activation. Once secreted, VWF multimers bind platelets and chaperone coagulation factor VIII in the circulation. Treatment of VWD focuses on increasing VWF plasma levels, but production and secretion of mutant VWF remain uninterrupted. Presence of circulating mutant VWF might, however, still affect normal hemostasis or functionalities of VWF beyond hemostasis. We hypothesized that inhibition of the production of mutant VWF improves the function of VWF overall and ameliorates VWD phenotypes. We previously proposed the use of allele-specific small-interfering RNAs (siRNAs) that target frequent VWF single nucleotide polymorphisms to inhibit mutant VWF. The aim of this study is to prove the functionality of these allele-specific siRNAs in endothelial colony-forming cells (ECFCs). We isolated ECFCs from a VWD type 2A patient with an intracellular multimerization defect, reduced VWF collagen binding, and a defective processing of proVWF to VWF. After transfection of an allele-specific siRNA that specifically inhibited expression of mutant VWF, we showed amelioration of the laboratory phenotype, with normalization of the VWF collagen binding, improvement in VWF multimers, and enhanced VWF processing. Altogether, we prove that allele-specific inhibition of the production of mutant VWF by siRNAs is a promising therapeutic strategy to improve VWD phenotypes.